AstraZeneca - On the Verge of a Breakdown - Respiratory Portfolio (Symbicort and Pulmicort) Threatened by Generics

April 2013 | 2 pages | ID: A04E693B9FEEN
MP Advisors

Abstracts

The respiratory portfolio of AZN which so far has withstood generics attack, is now giving away. Yesterday’s court ruling invalidating pulmicort respule patent and Teva filing a MAA in Europe for a generic equivalent of Symbicort has really shaken AZN base business. In addition recently Apotex announced invalidation of AZN Crestor patent in the Australia ($350m annual sales in 2012). We revise our 2013 core EPS estimate from $4.7 per share to $4.6 per share.

Companies mentioned

AstraZeneca